US Patent

US9186346 — Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients

Method of Use · Assigned to Sanofi SA · Expires 2034-02-04 · 8y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method for reducing the risk of an adverse interaction between the drugs teriflunomide and a substrate of certain proteins in multiple sclerosis patients.

USPTO Abstract

This invention relates to a method for managing the risk of an adverse interaction between teriflunomide and a substrate of breast cancer resistance protein (BCRP) and/or organic anion transporting polypeptide B1 and B3 (OATP1B1/B3).

Drugs covered by this patent

Aubagio (TERIFLUNOMIDE) · Sanofi

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1786`	—	Aubagio
`U-1786`	—	Aubagio

Patent Metadata

Patent number: US9186346
Jurisdiction: US
Classification: Method of Use
Expires: 2034-02-04
Drug substance claim: No
Drug product claim: No
Assignee: Sanofi SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.